Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.

Autor:	O'Horo JC; Division of Infectious Diseases, Rochester, Minnesota, USA ohoro.john@mayo.edu.; Division of Pulmonary and Critical Care Medicine, Rochester, Minnesota, USA., Osmon DR; Division of Infectious Diseases, Rochester, Minnesota, USA., Abu Saleh OM; Division of Infectious Diseases, Rochester, Minnesota, USA., Marcelin JR; Division of Infectious Diseases, Rochester, Minnesota, USA., Gharaibeh KA; Division of Nephrology and Hypertension, Rochester, Minnesota, USA., Hamadah AM; Division of Nephrology and Hypertension, Rochester, Minnesota, USA., Barwise AK; Division of Pulmonary and Critical Care Medicine, Rochester, Minnesota, USA., Kayhart BM; Pharmacy Services, Rochester, Minnesota, USA., McDonald JS; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., McDonald RJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Leung N; Division of Nephrology and Hypertension, Rochester, Minnesota, USA.; Division of Hematology, Rochester, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Jul 25; Vol. 61 (8). Date of Electronic Publication: 2017 Jul 25 (Print Publication: 2017).
DOI:	10.1128/AAC.00323-17
Abstrakt:	Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent non-contrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone. (Copyright © 2017 American Society for Microbiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu